CN115607596B - 一种具有降尿酸作用的养生酒及其制备方法 - Google Patents
一种具有降尿酸作用的养生酒及其制备方法 Download PDFInfo
- Publication number
- CN115607596B CN115607596B CN202211556126.8A CN202211556126A CN115607596B CN 115607596 B CN115607596 B CN 115607596B CN 202211556126 A CN202211556126 A CN 202211556126A CN 115607596 B CN115607596 B CN 115607596B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- wine
- uric acid
- health wine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 49
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229940116269 uric acid Drugs 0.000 title claims abstract description 49
- 230000036541 health Effects 0.000 title claims abstract description 36
- 230000001603 reducing effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims description 8
- 238000002386 leaching Methods 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 10
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 10
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 10
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 10
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 9
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 9
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 9
- 238000007865 diluting Methods 0.000 claims abstract description 9
- 239000008213 purified water Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims abstract description 8
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 8
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 3
- 230000001105 regulatory effect Effects 0.000 claims abstract description 3
- 244000298479 Cichorium intybus Species 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 35
- 244000163122 Curcuma domestica Species 0.000 claims description 14
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 14
- 235000003373 curcuma longa Nutrition 0.000 claims description 14
- 235000013976 turmeric Nutrition 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 9
- 244000010000 Hovenia dulcis Species 0.000 claims description 8
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000000643 oven drying Methods 0.000 claims description 6
- 229940052016 turmeric extract Drugs 0.000 claims description 6
- 235000020240 turmeric extract Nutrition 0.000 claims description 6
- 239000008513 turmeric extract Substances 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 18
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 240000006365 Vitis vinifera Species 0.000 abstract 1
- 235000014787 Vitis vinifera Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 10
- 201000005569 Gout Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000004677 Nylon Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229920001778 nylon Polymers 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 241000723343 Cichorium Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 244000185386 Thladiantha grosvenorii Species 0.000 description 5
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 229960003081 probenecid Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XULPLJSODQQHPH-UHFFFAOYSA-N Bergenin Natural products OCC1OC2C(OC(=O)c3cc(O)c(CO)c(O)c23)C(O)C1O XULPLJSODQQHPH-UHFFFAOYSA-N 0.000 description 1
- YWJXCIXBAKGUKZ-HJJNZUOJSA-N Bergenin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]2C3=C(O)C(OC)=C(O)C=C3C(=O)O[C@@H]21 YWJXCIXBAKGUKZ-HJJNZUOJSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 241000908494 Dioscorea nipponica Species 0.000 description 1
- 235000017008 Dioscorea nipponica Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 241000593522 Sargassum thunbergii Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003483 aging Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- -1 pachyman Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 238000003836 solid-state method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 235000001366 vegetable intake Nutrition 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
- C12G3/05—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
- C12G3/055—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides extracted from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有降尿酸功效的养生酒,是以葛根10~20重量份、枳椇子1~10重量份、茯苓1~10重量份、菊苣1~10重量份、山楂1~10重量份、橘皮1~10重量份、炒苦荞1~10重量份、罗汉果1~10重量份为原料,用10~20倍于原料总重量的65°白酒常温浸制不少于6天获取浸提液,再以3~4倍于浸提液体积的65°白酒稀释后,纯化水调整酒精度至42°得到的养生酒。本发明养生酒在降尿酸、增强免疫力等方面效果显著,长期服用可以有效治疗高尿酸血症。
Description
技术领域
本发明属于养生用酒技术领域,涉及一种具有降尿酸功效的养生酒,以及该养生酒的制备方法。
背景技术
我国人口老龄化趋势不断加快,人们工作、生活节奏加快,生存压力不断加大,致使处于亚健康状态的人群比例不断增高,人们对于保健品的需求也不断增加。因此,养生酒市场容量也呈现不断扩大的趋势。
近年来我国的高尿酸血症呈明显上升和年轻化趋势。我国高尿酸血症总体患病率为13.3%,患病人群约1.77亿,痛风总体发病率为1.1%,患病人数约为1466万。另一项数据显示,我国高尿酸血症及痛风患者中有近六成人群是18~35岁的年轻人。这就意味着痛风已经不再是以往人们心中认为的“中老年疾病”,以90后为代表的年轻群体也应该将防治痛风纳入自己的养生之道了,尤其是爱吃海鲜等高嘌呤食物、过度饮酒不节制、作息不规律、体重超标及经常吸烟的五大人群,更应加以重点关注。
高尿酸血症不仅是痛风的关键危险因素,也与肾脏疾病、高血压、糖尿病、心血管疾病等密切相关。因此,高尿酸血症已成为一个日益严重的公共卫生问题。有效降低尿酸水平是降低痛风发生风险及预防合并症发生发展的关键。
降尿酸治疗包括生活干预及药物干预。所有高尿酸血症患者均建议进行生活方式的干预,包括控制体重、规律运动、限制酒精及高嘌呤食物的摄入、鼓励奶制品和新鲜蔬菜的摄入等。而药物干预目前在临床上则重点应用于痛风患者,大部分接受药物治疗的高尿酸血症患者需要长期甚至终生服用降尿酸药物。对于无症状性高尿酸血症患者,欧美指南多不推荐药物干预,而我国则建议血尿酸≥540µmol/L或≥480µmol/L且有合并症的患者启动药物治疗。
目前临床应用的降尿酸药物主要有三类。
第一类是尿酸生成抑制剂,通过抑制黄嘌呤氧化酶(XO)抑制尿酸合成,代表药物有别嘌醇和非布司他,均为临床一线用药。别嘌醇具有良好的降尿酸效果且价格较低廉,但其具有诱发致死性超敏反应的风险。此外,长期使用别嘌醇会引起胃肠道不适、肝功能异常、血液系统损害及增加死亡风险。非布司他降尿酸效果显著,但价格昂贵且具有潜在的心脏相关性死亡风险,建议合并有心脑血管疾病患者慎用。
第二类是促尿酸排泄类药物,通过抑制肾小管重吸收尿酸盐来降低血清尿酸水平,代表药物有苯溴马隆和丙磺舒。此类药物不推荐用于肾结石患者,服用时需大量饮水及碱化尿液。此外,苯溴马隆具有潜在肝毒性,不推荐用于肝病患者。丙磺舒与阿司匹林及其他水杨酸盐同用时降尿酸疗效下降,且可增加抗生素、吲哚美辛等药物血药浓度,其临床应用受到限制。
第三类是促尿酸溶解类药,代表药为拉布立酶,属于重组尿酸氧化酶,价格昂贵,主要用于因化疗引起的高尿酸血症患者,该药的安全性仍需要进一步验证。
鉴于目前临床应用的降尿酸药物均有一定的副作用且大多治疗成本较高,患者依从性差,积极寻找安全、廉价、有效的防治高尿酸血症的策略,具有重要的临床和公共卫生意义。
此外,已有许多研究发现,很多天然产物具有XO的抑制作用,而且对体内正常嘌呤代谢不造成影响,降尿酸效果显著,副作用小。一些天然产物还具有抗炎和抗氧化应激的作用,如槲皮素和芦丁可以阻断果糖诱导的高尿酸小鼠体内NLRP3炎症小体的激活,对肾脏起到潜在的保护作用。目前已有的研究中,天然产物中具有治疗高尿酸血症作用的有效成分包括黄酮类(如槲皮素、芹菜素、葛根素等)、皂苷类(如穿山龙总皂苷、萆薢总皂苷和七叶莲皂苷等)、多糖类(如茯苓多糖、枸杞多糖等)、香豆素类(如秦皮总香豆素和岩白菜素等)、多酚类(如鼠尾藻多酚和茶多酚等)及其他(如水蛭素、白藜芦醇、菊苣酸等)。这些天然产物主要通过抑制尿酸产生和促进尿酸排泄两种机制来发挥治疗高尿酸血症作用,往往具有多环节、多层次、多靶点的调控机制,在高尿酸血症新型治疗药物的开发中具有广阔的应用前景。
中药在促进尿酸排泄的基础上拥有良好的安全性,不仅为防治高尿酸血症及痛风提供了多方面、多角度的治疗方案,同时发现了一些新的降尿酸作用靶点,如菊苣提取物及大黄中的有效成分大黄酸可以有效促进尿酸自肠道排出,对于肾功能不全患者的治疗具有重要意义。但中药防治高尿酸血症及痛风也存有不足之处,当下中药用于临床治疗高尿酸血症主要还是通过方剂形式,由于中药机制及其作用靶点复杂,多种单味药组合后的具体有效成分和/或作用机制也有待明确,攻克单味中药及方剂的具体机制仍是当前中药迈向国际化的重点。
所有的高尿酸血症患者均建议进行生活方式干预,其中包括限制酒精摄入,这就严重影响了爱好饮酒的高尿酸人群的生活质量。
事实上,药酒疗法属于中医的独特疗法,数千年来,祖国医药医学在药酒的使用方面积累了丰富的经验。药酒是药与酒的结合,二者的配合使得药增酒性,酒助药行,既包含了药的特性,又包含了酒的特性,作用很广。
发明内容
本发明的目的是提供一种具有降尿酸功效的养生酒,以解决饮酒引起的尿酸增高问题,在降尿酸的同时,还可增强机体免疫力,满足爱好饮酒的高尿酸人群需求,提高其生活质量。
本发明所述的具有降尿酸功效的养生酒是以葛根10~20重量份、枳椇子1~10重量份、茯苓1~10重量份、菊苣1~10重量份、山楂1~10重量份、橘皮1~10重量份、炒苦荞1~10重量份、罗汉果1~10重量份为原料,用10~20倍于原料总重量的65°白酒常温浸制不少于6天获取浸提液,再以3~4倍于浸提液体积的65°白酒稀释后,纯化水调整酒精度至42°得到的养生酒。
其中,本发明对于所使用65°白酒的来源并无特殊要求,可以是各种市售的65°纯粮白酒。进一步地,本发明优选使用各种以梁谷为原料,经传统固态法发酵、蒸馏、陈酿、勾兑而成的,未添加酒精及任何非白酒发酵产生呈香呈味物质的清香型纯粮酿造原浆白酒。
本发明还提供了一种所述具有降尿酸功效的养生酒的制备方法,需要说明的是,所述方法是优化的但并非唯一的本发明养生酒的制备方法。
1)、将葛根、枳椇子、菊苣、山楂、橘皮清洗干净后,于50℃烘干。
2)、将所述重量份数的烘干的葛根、枳椇子、菊苣、山楂、橘皮与所述重量份数的茯苓、炒苦荞、罗汉果加入相当于原料总重量10~20倍的65°白酒中搅拌均匀,浸制不少于6天,过滤出浸提液。
3)、将浸提液与65°白酒以体积比为1∶3~4进行混合,调整浸出药物的浓度,得到粗调酒。
4)、以纯化水稀释粗调酒,调整酒精度至42°,得到调制酒。
进一步地,本发明还可以在调制酒中加入姜黄提取液作为色素进行调色。
所述姜黄提取液是将姜黄用15倍量的65°白酒浸制不少于6天后过滤出的滤液。
更具体地,所述姜黄提取液的加入量为养生酒质量的0.2~0.3%。
更进一步地,本发明还可以在所述制备的养生酒中加入低聚果糖。
更具体地,优选是在每100ml养生酒中加入5~10g低聚果糖。
更进一步地,本发明还可以将制备的养生酒于冰箱中2~8℃低温静置24~48h后,再经硅藻土抽滤处理。低温静置和硅藻土过滤有益于去除物料中的沉淀和杂质,增加养生酒的澄清度。
本发明具有降尿酸功效养生酒的主要特点之一是重用葛根,为剂量之最,葛根甘、辛而凉,其性清轻升发,入脾胃经,既能解肌退热,又能升发脾胃清阳之气而治下利,是一物而二任也,故为君药;枳椇子味甘,性平,入胃经,解酒毒,止渴除烦,止呕,利大小便,茯苓功能利水渗湿,药性平和,利水而不伤正气,为利水渗湿要药,菊苣味微苦、性凉,有清热利湿、健胃的功效,三者共同辅助葛根增强利水之功效,为臣药;山楂性味酸甘,微温,归肺、胃、肝三经,有消食化积、活血行气之功,橘皮味辛、苦,入手太阴肺经,降浊阴而止呕哕,行滞气而泻郁满,降浊行气以助利水,共为佐药;罗汉果味甘,性凉,归肺、大肠经,有润肺止咳、生津止渴的功效,为使药。各组分药效协同增效,辅以白酒以助药行,起到降尿酸的作用。
本发明养生酒通过上述药物的科学合理配比,不仅在色泽、口感、香味等感官品质上具有较优的表现,而且经动物实验研究表明,所述养生酒在降尿酸、增强免疫力等方面效果显著,长期服用可以有效治疗高尿酸血症。
具体实施方式
下面结合实施例对本发明的具体实施方式作进一步的详细描述。以下实施例仅用于更加清楚地说明本发明的技术方案,从而使本领域技术人员能很好地理解和利用本发明,而不是限制本发明的保护范围。
本发明实施例中涉及到的生产工艺、实验方法或检测方法,若无特别说明,均为现有技术中的常规方法,且其名称和/或简称均属于本领域内的常规名称,在相关用途领域内均非常清楚明确,本领域技术人员能够根据该名称理解常规工艺步骤并应用相应的设备,按照常规条件或制造商建议的条件进行实施。
本发明实施例中使用的各种仪器、设备、原料或试剂,并没有来源上的特殊限制,均为可以通过正规商业途径购买获得的常规产品,也可以按照本领域技术人员熟知的常规方法进行制备。
实施例1。
将葛根、枳椇子、菊苣、山楂和橘皮清洗干净后,于烘干箱中50℃烘干。
称取葛根10g、枳椇子1g、茯苓5g、菊苣10g、山楂10g、橘皮5g、炒苦荞10g、罗汉果1g加入玻璃罐中,加入780g的65°清香型白酒,搅拌均匀,常温下浸制6天后,以250目尼龙纱布进行过滤得到浸提液。
将浸提液与65°清香型白酒以体积比为1:3.5进行混合,得到粗调酒。
称取姜黄1g加入玻璃瓶中,再加入15g的65°清香型白酒,搅拌均匀,常温下浸制6天后,以250目尼龙纱布进行过滤,得到姜黄滤液。
用纯化水将上述得到的粗调酒稀释至酒精度42°,再加入养生酒质量0.2~0.3%的姜黄滤液,得到透亮明黄的调制酒。
按照每100ml加7g的用量,在调制酒中加入低聚果糖,于冰箱中4℃静置24h,经硅藻土抽滤,灌装得到本发明具有降尿酸功效的养生酒。
实施例2。
将葛根、枳椇子、菊苣、山楂和橘皮清洗干净后,于烘干箱中50℃烘干。
称取葛根20g、枳椇子10g、茯苓1g、菊苣5g、山楂5g、橘皮1g、炒苦荞1g、罗汉果5g加入玻璃罐中,加入480g的65°清香型白酒,搅拌均匀,常温下浸制6天后,以250目尼龙纱布进行过滤得到浸提液。
将浸提液与65°清香型白酒以体积比为1:3.5进行混合,得到粗调酒。
称取姜黄3g加入玻璃瓶中,再加入45g的65°清香型白酒,搅拌均匀,常温下浸制6天后,以250目尼龙纱布进行过滤,得到姜黄滤液。
用纯化水将上述得到的粗调酒稀释至酒精度42°,再加入养生酒质量0.2~0.3%的姜黄滤液,得到透亮明黄的调制酒。
按照每100ml加5g的用量,在调制酒中加入低聚果糖,于冰箱中4℃静置24h,经硅藻土抽滤,灌装得到本发明具有降尿酸功效的养生酒。
实施例3。
将葛根、枳椇子、菊苣、山楂和橘皮清洗干净后,于烘干箱中50℃烘干。
称取葛根15g、枳椇子5g、茯苓10g、菊苣1g、山楂1g、橘皮10g、炒苦荞5g、罗汉果10g加入玻璃罐中,加入1140g的65°清香型白酒,搅拌均匀,常温下浸制6天后,以250目尼龙纱布进行过滤得到浸提液。
将浸提液与65°清香型白酒以体积比为1:3.5进行混合,得到粗调酒。
称取姜黄10g加入玻璃瓶中,再加入150g的65°清香型白酒,搅拌均匀,常温下浸制6天后,以250目尼龙纱布进行过滤,得到姜黄滤液。
用纯化水将上述得到的粗调酒稀释至酒精度42°,再加入养生酒质量0.2~0.3%的姜黄滤液,得到透亮明黄的调制酒。
按照每100ml加5g的用量,在调制酒中加入低聚果糖,于冰箱中4℃静置24h,经硅藻土抽滤,灌装得到本发明具有降尿酸功效的养生酒。
对照例1。
将葛根、枳椇子、山楂和橘皮清洗干净后,于烘干箱中50℃烘干。
称取葛根20g、枳椇子10g、山楂5g、橘皮1g、炒苦荞1g、罗汉果5g于玻璃罐中,加入420g的65°清香型白酒,搅拌均匀,常温下浸制6天后,以250目尼龙纱布进行过滤得到浸提液。
将浸提液与65°清香型白酒以体积比为1:3.5进行混合,得到粗调酒。
称取姜黄3g加入玻璃瓶中,再加入45g的65°清香型白酒,搅拌均匀,常温下浸制6天后,以250目尼龙纱布进行过滤,得到姜黄滤液。
用纯化水将上述得到的粗调酒稀释至酒精度42°,再加入养生酒质量0.2~0.3%的姜黄滤液,得到透亮明黄的调制酒。
按照每100ml加5g的用量,在调制酒中加入低聚果糖,于冰箱中4℃静置24h,经硅藻土抽滤,灌装得到养生酒对照样1。
对照例2。
取实施例2制备的具有降尿酸功效的养生酒,放入旋蒸仪中进行旋蒸,将其中的酒精去除干净后,制备得到无酒精的样品作为养生酒对照样2。
应用例1:降尿酸养生酒对高尿酸血症小鼠的作用试验。
采用实施例2制备的降尿酸养生酒进行试验,并以对照样1和对照样2制备样品进行对照。
实验动物为KM小鼠,SPF级,雌性,体重17~21g,购自西安交通大学医学部动物试验中心,许可证编号SCXK(陕)2018-001,批号20220511,质量合格证编号NO.2450。
适应性饲养一周后,将KM小鼠随机分成空白组、模型组,以及试验组、对照1组和对照2组三个样品组。
除空白组外,其他各组小鼠酵母膏30g/(kg·d)灌胃建模,每天1次,连续13d。建模期间,试验组、对照1组和对照2组按照11.1ml/kg灌胃对应受试物。
第14d给药1h后,空白组腹腔注射生理盐水,其余各组腹腔注射氧嗪酸钾盐300mg/kg 1次,注射1h后摘眼球取血,分离血清,取上清液用于UA(尿酸)测定。
SPSS软件分析,P<0.05表明具有显著性差异,P<0.01表明极显著。
注:与空白组比较,#P<0.05;与模型组比较,*P<0.05,**P<0.01。
与空白组相比,模型组小鼠的血清UA水平显著升高(P<0.05),建模成功。
试验组、对照1组和对照2组小鼠的血清UA水平与模型组相比,均有明显降低(P<0.05),其中,试验组降低最为显著(P<0.01),且与对照1组、对照2组比较也有显著性差异。
其中,对照2组的药物用量和制备过程均与试验组相同,只是移除了酒精,其降低血清UA的作用就明显下降,充分证明了本发明养生酒中白酒以助药行的作用效果。
上述试验结果表明,本发明养生酒能显著降低高尿酸血症小鼠的血清UA水平。
应用例2:降尿酸养生酒的降脂功效试验。
实验动物为KM小鼠,SPF级,雌性,体重17~21g,购自西安交通大学医学部动物试验中心,许可证编号SCXK(陕)2018-001,批号20220511,质量合格证编号NO.2450。
适应性饲养一周后,将KM小鼠随机分成空白组和模型组,空白组给予维持饲料,模型组给予模型饲料(即高脂饲料)。
每周称量体重1次,2周后不禁食采血(眼内眦或尾部),采血后尽快分离血清,测定血清TC、TG、LDL-C、HDL-C水平。
根据TC水平将模型组随机分成对照组和试验组,组间比较TC、TG、LDL-C、HDL-C差异均无显著性,且对照组和试验组与空白组比较,TC、TG、LDL-C、HDL-C升高差异均有显著性,模型构建成功。
分组后,试验组每天经口给予实施例2样品,空白组和对照组同时给予同体积的相应溶剂,且空白组继续给予维持饲料,对照组和试验组继续给予模型饲料。
定期称量体重,按要求检测TC、TG、LDL-C、HDL-C数据变化。
注:与空白组比较,#P<0.05;与对照组比较,*P<0.05。
与空白组比较,对照组小鼠的血清TG、TC、LDL、HDL水平显著升高,与对照组相比,试验组对小鼠的血清TG、TC、LDL均有降低,HDL变化无显著性,表明本发明养生酒能够降低TG、TC、LDL水平,维持HDL水平。
本发明以上实施例并没有详尽叙述所有的细节,也不限制本发明仅为以上所述实施例。本领域普通技术人员在不脱离本发明原理和宗旨的情况下,针对这些实施例进行的各种变化、修改、替换和变型,均应包含在本发明的保护范围之内。
Claims (8)
1.一种具有降尿酸功效的养生酒,是以葛根10~20重量份、枳椇子1~10重量份、茯苓1~10重量份、菊苣1~10重量份、山楂1~10重量份、橘皮1~10重量份、炒苦荞1~10重量份、罗汉果1~10重量份为原料,用10~20倍于原料总重量的65°白酒常温浸制不少于6天获取浸提液,再以3~4倍于浸提液体积的65°白酒稀释后,纯化水调整酒精度至42°得到的养生酒。
2.权利要求1所述具有降尿酸功效的养生酒的制备方法,包括:
1)、将葛根、枳椇子、菊苣、山楂、橘皮清洗干净后,于50℃烘干;
2)、将所述重量份数的烘干的葛根、枳椇子、菊苣、山楂、橘皮与所述重量份数的茯苓、炒苦荞、罗汉果加入相当于原料总重量10~20倍的65°白酒中搅拌均匀,浸制不少于6天,过滤出浸提液;
3)、将浸提液与65°白酒以体积比为1∶3~4进行混合,调整浸出药物的浓度,得到粗调酒;
4)、以纯化水稀释粗调酒,调整酒精度至42°,得到调制酒。
3.根据权利要求2所述的制备方法,其特征是还包括在调制酒中加入姜黄提取液作为色素进行调色。
4.根据权利要求3所述的制备方法,其特征是所述姜黄提取液是将姜黄用15倍量的65°白酒浸制不少于6天后过滤出的滤液。
5.根据权利要求3或4所述的制备方法,其特征是所述姜黄提取液的加入量为养生酒质量的0.2~0.3%。
6.根据权利要求2所述的制备方法,其特征是还包括在制备的养生酒中加入低聚果糖。
7.根据权利要求6所述的制备方法,其特征是在每100ml养生酒中加入5~10g低聚果糖。
8.根据权利要求2所述的制备方法,其特征是将制备的养生酒于冰箱中2~8℃低温静置24~48h后,再经硅藻土抽滤处理。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211556126.8A CN115607596B (zh) | 2022-12-06 | 2022-12-06 | 一种具有降尿酸作用的养生酒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211556126.8A CN115607596B (zh) | 2022-12-06 | 2022-12-06 | 一种具有降尿酸作用的养生酒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115607596A CN115607596A (zh) | 2023-01-17 |
CN115607596B true CN115607596B (zh) | 2023-12-19 |
Family
ID=84880262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211556126.8A Active CN115607596B (zh) | 2022-12-06 | 2022-12-06 | 一种具有降尿酸作用的养生酒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115607596B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109172670A (zh) * | 2018-11-13 | 2019-01-11 | 张洪搏 | 具有肝肾代谢调节功能的中药组合物及其制备方法 |
CN109349384A (zh) * | 2018-11-16 | 2019-02-19 | 万顺宝(肇庆)实业有限公司 | 一种具有降低尿酸功效的神秘果复合茶及其制备方法 |
CN110893202A (zh) * | 2019-12-20 | 2020-03-20 | 威海松龄诺可佳中药饮片股份有限公司 | 治疗痛风的药酒 |
CN112057553A (zh) * | 2020-09-30 | 2020-12-11 | 广西玉林巨安保健品有限公司 | 一种降尿酸组合物及其制备方法和应用 |
-
2022
- 2022-12-06 CN CN202211556126.8A patent/CN115607596B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109172670A (zh) * | 2018-11-13 | 2019-01-11 | 张洪搏 | 具有肝肾代谢调节功能的中药组合物及其制备方法 |
CN109349384A (zh) * | 2018-11-16 | 2019-02-19 | 万顺宝(肇庆)实业有限公司 | 一种具有降低尿酸功效的神秘果复合茶及其制备方法 |
CN110893202A (zh) * | 2019-12-20 | 2020-03-20 | 威海松龄诺可佳中药饮片股份有限公司 | 治疗痛风的药酒 |
CN112057553A (zh) * | 2020-09-30 | 2020-12-11 | 广西玉林巨安保健品有限公司 | 一种降尿酸组合物及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
健脾化湿汤对高尿酸血症模型大鼠的影响;陈健文;周源;薛照芸;李承;郭键;周里岩;蒋建敏;;中药材;36(09);1486-1489 * |
具有降尿酸功效的食品研究进展;张瑛毓;中国食物与营养;26(01);50-53 * |
Also Published As
Publication number | Publication date |
---|---|
CN115607596A (zh) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102198262B (zh) | 一种治疗小儿轮状病毒性肠炎的中药制剂及其制备方法 | |
CN107997176A (zh) | 一种防治小儿积食厌食的健胃消食保健食品 | |
CN102772781A (zh) | 一种治疗慢性结肠炎的中药制剂及其制备方法 | |
CN101773580B (zh) | 一种用于治疗小儿急性支气管炎的中药组合物及制备方法 | |
CN104857436B (zh) | 具有抗肝癌活性的中药复方组合物及其制备方法和应用 | |
CN104757361B (zh) | 一种治疗咽喉炎的保健饮料 | |
CN103977390B (zh) | 一种生姜洋葱药酒组合物的制备方法及其用途 | |
CN115607596B (zh) | 一种具有降尿酸作用的养生酒及其制备方法 | |
CN110051817A (zh) | 一种降低尿酸的中药组合及其应用 | |
CN110772564A (zh) | 一种具有调节抑郁情绪作用的中药提取物组合物及其制备方法和中药制剂 | |
CN101332247A (zh) | 一种治疗小儿咳嗽的中药的制备方法 | |
CN103920140A (zh) | 一种人用降糖减肥降脂复方制剂 | |
CN101143203B (zh) | 一种具有护肝养胃功能的复方口服液 | |
CN102274428B (zh) | 一种具有治疗肠易激综合症作用的药物组合物及其制备方法和应用 | |
CN107648335B (zh) | 调节动脉粥样硬化自噬与凋亡的中药组合物及制备方法 | |
CN106668040A (zh) | 一种防治新生儿黄疸的药物组合物及制备方法和应用 | |
CN107126450B (zh) | 鼠麹草提取物、鼠麹草有效物质富集物,制备方法与应用 | |
CN106138259B (zh) | 一种治疗风热感冒的中药组合物及其制备方法 | |
CN108210595A (zh) | 治疗慢加急性肝衰竭的中药组合物及其制备方法和应用 | |
CN103191243A (zh) | 由黄连、吴茱萸组成的药物组合物的用途及其制备方法 | |
CN103690771B (zh) | 用于治疗羔羊大肠杆菌病的药物及其制备方法 | |
CN114259540B (zh) | 一种治疗气阴两虚证糖尿病的中药组合物及其制备方法和用途 | |
CN116036174B (zh) | 一种治疗肺结节的药物及其制备方法 | |
CN102579713B (zh) | 治疗儿童肥胖症的中药及制备方法 | |
CN108938749B (zh) | 一种药物组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |